» Articles » PMID: 29472714

Oncogene-induced Senescence Mediated by C-Myc Requires USP10 Dependent Deubiquitination and Stabilization of P14ARF

Overview
Specialty Cell Biology
Date 2018 Feb 24
PMID 29472714
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Oncogene-induced senescence (OIS) is a critical tumor-suppressor mechanism, which prevents hyper-proliferation and transformation of cells. c-Myc promotes OIS through the transcriptional activation of p14ARF followed by p53 activation. Although the oncogene-mediated transcriptional regulation of p14ARF has been well addressed, the post-translational modification of p14ARF regulated by oncogenic stress has yet to be investigated. Here, we found that c-Myc increased p14ARF protein stability by inducing the transcription of ubiquitin-specific protease 10 (USP10). USP10, in turn, mediated the deubiquitination of p14ARF, preventing its proteasome-dependent degradation. USP10-null mouse embryonic fibroblasts and human primary cells depleted of USP10 bypassed c-Myc-induced senescence via the destabilization of p14ARF, and these cells displayed accelerated hyper-proliferation and transformation. Clinically the c-Myc-USP10-p14ARF axis was disrupted in non-small cell lung cancer patients, resulting in significantly worse overall survival. Our studies indicate that USP10 induced by c-Myc has a crucial role in OIS by maintaining the stability of key tumor suppressor p14ARF.

Citing Articles

Deubiquitinase USP10 promotes osteosarcoma autophagy and progression through regulating GSK3β-ULK1 axis.

Feng Z, Ou Y, Deng X, Deng M, Yan X, Chen L Cell Biosci. 2024; 14(1):111.

PMID: 39218913 PMC: 11367994. DOI: 10.1186/s13578-024-01291-9.


Stress-induced epinephrine promotes hepatocellular carcinoma progression via the USP10-PLAGL2 signaling loop.

Wang C, Ni J, Zhai D, Xu Y, Wu Z, Chen Y Exp Mol Med. 2024; 56(5):1150-1163.

PMID: 38689092 PMC: 11148159. DOI: 10.1038/s12276-024-01223-0.


Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.

Song B, Yang P, Zhang S Cancer Commun (Lond). 2024; 44(3):297-360.

PMID: 38311377 PMC: 10958678. DOI: 10.1002/cac2.12520.


A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.

Long J, Chen X, Shen Y, Lei Y, Mu L, Wang Z Cell Rep Med. 2023; 4(11):101286.

PMID: 37951217 PMC: 10694671. DOI: 10.1016/j.xcrm.2023.101286.


Deubiquitylating Enzymes in Cancer and Immunity.

Ren J, Yu P, Liu S, Li R, Niu X, Chen Y Adv Sci (Weinh). 2023; 10(36):e2303807.

PMID: 37888853 PMC: 10754134. DOI: 10.1002/advs.202303807.


References
1.
Kamijo T, Bodner S, Van de Kamp E, Randle D, Sherr C . Tumor spectrum in ARF-deficient mice. Cancer Res. 1999; 59(9):2217-22. View